Introduction
Method
Study Setting
Study Design
Data Sources
Statistical Methods
Ethical Approval
Results
Study Population
Factor | Host | Refugeea
|
p value |
---|---|---|---|
Female ∑, n (%) | 33/148 (22) | 55/153 (36) | 0.006b
|
Age, median years (IQR) | 40 (35, 48) | 35 (31, 39) | <0.001c
|
Unemployed, n (%) | 50/148 (34) | 91/152 (60) | <0.001d
|
Educational status, n (%) | |||
None | 3/148 (2) | 8/153 (5) | <0.001b
|
Any primary | 16/148 (11) | 60/153 (39) | |
Any secondary or above | 129/148 (87) | 85/153 (56) | |
Marital status, n (%) | |||
Single | 90/148 (61) | 61/153 (40) | <0.001b
|
Married | 58/148 (39) | 92/153 (60) | |
Nationality | |||
Malaysian | 148/148 (100) | 0/151 (0) | <0.001b
|
Burmese | 0/148 (0) | 146/151 (97) | |
Other | 0/148 (0) | 5/151 (3) | |
Current defaulters, n (%)e
| 16/148 (11) | 10/153 (7) | 0.19d
|
Viral load, copies/mL (%) | |||
Suppressed <40 | 112/144 (78) | 112/152 (74) | 0.41d
|
Not suppressed ≥40 | 32/144 (22) | 40/152 (26) | |
Most recent routine CD4, median cells/μL (IQR)f
| 350 (202, 486) | 278 (182, 423) | 0.03c
|
Time on HAART, median weeks (IQR)g
| 153 (63, 298) | 61 (35, 108) | <0.001c
|
Time since HIV diagnosis, median weeks (IQR)h
| 315 (152, 571) | 113 (66, 170) | <0.001c
|
Time since entry to host country, median weeks (IQR) | NA | 186 (105, 324) | NA |
Time since refugee status approval, median weeks (IQR)i
| NA | 91 (54, 149) | NA |
Virological and Adherence Outcomes
Time on HAART (weeks) | Group | ≥40 copies/mL, n (%) | Total, n (%) |
p valuea
|
---|---|---|---|---|
Allb
| Host | 32 (22) | 144 (100) | 0.41 |
Refugee | 40 (26) | 152 (100) | ||
<25 | Host | 12 (67) | 18 (100) | 1.00 |
Refugee | 17 (59) | 29 (100) | ||
≥25 | Host | 20 (16) | 125 (100) | 0.54 |
Refugee | 23 (19) | 121 (100) |
Adherence measure | Host, n (%) | Refugee, n (%) |
p valuea
|
---|---|---|---|
Dose-by-dose self-report (four days) | (n = 148) | (n = 153) | 0.20 |
0+ | 6 (4) | 11 (7) | |
80+ | 0 (0) | 1 (1) | |
95+ | 142 (96) | 141 (92) | |
Visual analogue scale self-report (one month) | (n = 148) | (n = 153) | 0.79 |
0+ | 11 (7) | 11 (7) | |
80+ | 33 (22) | 32 (21) | |
95+ | 104 (70) | 110 (72) | |
Pharmacy claim adherence (24 months)b
| (n = 143) | (n = 136) | 0.15 |
0+ | 14 (10) | 9 (7) | |
80+ | 34 (24) | 26 (19) | |
95+ | 95 (66) | 101 (74) |
Risk Factors for Unsuppressed Virological Outcomes
Factor | Prevalence ≥40 copies/mL, n/N (%)a
|
p value, crude odds ratio (95 % CI) |
p value, adjusted odds ratio (95 % CI)b
|
---|---|---|---|
Age group (years)c
|
p = 0.69 |
p = 0.68 | |
18− | 5/25 (20) | 1 | 1 |
30− | 18/114 (16) | 0.90 (0.52, 1.55) | 1.15 (0.60, 2.20) |
40+ | 13/83 (16) | ||
Refugee status |
p = 0.19 |
p = 0.60 | |
Host | 15/114 (13) | 1 | 1 |
Refugee | 21/108 (19) | 1.59 (0.77, 3.28) | 1.28 (0.52, 3.14) |
Time on HAART (years)c
|
p = 0.79 |
p = 0.56 | |
0− | 7/46 (15) | 1 | 1 |
1− | 9/57 (16) | 1.06 (0.68, 1.67) | 1.17 (0.69, 1.96) |
2+ | 20/119 (17) | ||
Sex |
p = 0.04 |
p = 0.05 | |
Male | 30/155 (19) | 1 | 1 |
Female/transgender | 6/67 (9) | 0.41 (0.16, 1.04) | 0.39 (0.14, 1.05) |
Time from diagnosis to start (weeks)c
|
p = 0.07 |
p = 0.04 | |
0− | 19/98 (19) | 1 | 1 |
25− | 8/30 (27) | 0.69 (0.47, 1.03) | 0.64 (0.41, 0.99) |
50+ | 9/94 (10) | ||
HAART regimen, dosing |
p = 0.32 |
p = 0.13 | |
EFV-based | 21/140 (15) | 1 | 1 |
NVP-based | 12/74 (16) | 1.10 (0.51, 2.38) | 1.03 (0.44, 2.43) |
Other | 3/8 (38) | 3.40 (0.76, 15.31) | 6.00 (1.14, 31.74) |
Current employment |
p = 0.23 |
p = 0.21 | |
No | 13/101 (13) | 1 | 1 |
Yes | 23/121 (19) | 1.59 (0.76, 3.32) | 1.70 (0.74, 3.95) |
Mother tongue |
p = 0.19 |
p = 0.26 | |
Bahasa Malaysia (Malay) | 5/39 (13) | 1 | 1 |
Tamil | 5/26 (19) | 1.62 (0.42, 6.27) | 1.56 (0.36, 6.73) |
Chinese dialects | 3/46 (7) | 0.47 (0.11, 2.13) | 0.47 (0.09, 2.32) |
Chin dialects | 13/54 (24) | 2.16 (0.70, 6.66) | 6.21 (0.57, 67.53) |
Burmese | 3/24 (13) | 0.97 (0.21, 4.49) | 2.52 (0.17, 38.58) |
Other | 7/33 (21) | 1.83 (0.52, 6.43) | 3.20 (0.30, 34.63) |
Household sizec
|
p = 0.73 |
p = 0.97 | |
1− | 9/56 (15) | 1 | 1 |
3− | 17/112 (15) | 1.09 (0.66, 1.82) | 1.01 (0.59, 1.73) |
7+ | 10/54 (19) | ||
No. dependent minors in household |
p = 0.59 |
p = 0.98 | |
0 | 23/133 (17) | 1 | 1 |
1+ | 13/89 (15) | 0.82 (0.39, 1.72) | 1.01 (0.44, 2.33) |
Temporary migration (≥1 continuous month in past year) |
p < 0.001 |
p = 0.002 | |
No | 23/187 (12) | 1 | 1 |
Yes | 13/35 (37) | 4.21 (1.87, 9.50) | 4.12 (1.70, 9.99) |
Pathway to diagnosis |
p = 0.50 |
p = 0.65 | |
Voluntary test | 7/43 (16) | 1 | 1 |
Mandatory test | 8/40 (20) | 1.29 (0.42, 3.94) | 2.01 (0.56, 7.18) |
Illness/hospitalisation | 16/88 (18) | 1.14 (0.43, 3.03) | 1.00 (0.34, 2.93) |
Other | 5/51 (10) | 0.56 (0.16, 1.91) | 1.07 (0.27, 4.25) |
Average time to clinic (hours) |
p = 0.01 |
p = 0.02 | |
0− | 6/74 (8) | 1 | 1 |
1+ | 30/148 (20) | 2.88 (1.14, 7.27) | 3.05 (1.09, 8.49) |
Regimen switch, ever |
p = 0.20 |
p = 0.07 | |
No | 16/120 (13) | 1 | 1 |
Yes | 20/102 (20) | 1.59 (0.77, 3.25) | 2.14 (0.94, 4.85) |
Unable to refill prescription, past three months |
p = 0.41 |
p = 0.44 | |
No | 35/210 (17) | 1 | 1 |
Yes | 1/12 (8) | 0.45 (0.06, 3.64) | 0.45 (0.05, 4.08) |
Any symptom or side-effect, past four weeks |
p = 0.23 |
p = 0.41 | |
No | 6/54 (11) | 1 | 1 |
Yes | 30/168 (18) | 1.74 (0.68, 4.44) | 1.51 (0.55, 4.19) |
Food securityd
|
p = 0.17 |
p = 0.23 | |
Secure | 10/84 (12) | 1 | 1 |
Insecure | 26/138 (19) | 1.72 (0.78, 3.77) | 1.83 (0.67, 5.00) |
Satisfaction with primary health care provider, mean scoree
| Mean = 4.21; SD = 0.70 |
p = 0.85; 0.95 (0.57, 1.59) |
p = 0.64; 0.88 (0.51, 1.51) |
Factor | Prevalence ≥40 copies/mL, n/N (%) |
p value, crude odds ratio (95 % CI) |
p value, adjusted odds ratio (95 % CI)a
|
---|---|---|---|
Adherence self-efficacy (self-rated ability to take medications as prescribed over previous month)b
|
p = 0.37 |
p = 0.95 | |
Excellent | 16/99 (16) | 1 | 1 |
Good/very good | 14/105 (13) | 1.30 (0.74, 2.26) | 1.02 (0.56, 1.86) |
Very poor/poor/fair | 6/18 (33) | ||
Serostatus disclosure to partner |
p = 0.67 |
p = 0.77 | |
No | 4/22 (18) | 1 | 1 |
Yes | 17/120 (14) | 0.74 (0.22, 2.46) | 1.11 (0.29, 4.23) |
No partner | 15/80 (19) | 1.04 (0.31, 3.52) | 1.45 (0.38, 5.53) |
Serostatus disclosure to family/friends |
p = 0.23 |
p = 0.49 | |
No | 10/81 (12) | 1 | 1 |
Yes | 26/141 (18) | 1.61 (0.73, 3.53) | 1.37 (0.56, 3.34) |
Alcohol use, past month |
p = 0.29 |
p = 0.69 | |
Never | 24/164 (15) | 1 | 1 |
One or more times | 12/58 (21) | 1.52 (0.71, 3.28) | 0.83 (0.33, 2.06) |
Use of illegal/harmful substances, past six months |
p = 0.23 |
p = 0.83 | |
No | 32/208 (15) | 1 | 1 |
Yes | 4/14 (29) | 2.20 (0.65, 7.45) | 1.18 (0.27, 5.31) |
Use of traditional medicines, past six months |
p = 0.46 |
p = 0.75 | |
No | 29/188 (15) | 1 | 1 |
Yes | 7/34 (21) | 1.48 (0.57, 3.57) | 1.31 (0.47, 3.70) |
No. of reported barriers to adherenceb
|
p = 0.46 |
p = 0.89 | |
0 | 13/82 (16) | 1 | 1 |
1+ | 8/67 (12) | 1.13 (0.82, 1.56) | 1.03 (0.71, 1.49) |
3+ | 8/36 (22) | ||
5+ | 7/37 (19) | ||
Knowledge of HIV and AIDS (% correct of four questions) |
p = 0.15 |
p = 0.23 | |
0+ | 1/18 (6) | 1 | 1 |
50+ | 35/204 (17) | 3.52 (0.45, 27.33) | 3.21 (0.37, 28.05) |
Factor | Prevalence ≥40 copies/mL, n/N (%) |
p value, crude odds ratio (95 % CI) |
p value, adjusted odds ratio (95 % CI)a
|
---|---|---|---|
Adherence to medication schedule, self-reported |
p = 0.44 |
p = 0.81 | |
Never, sometimes, half of the time, most of the time | 12/62 (19) | 1 | 1 |
All of the time | 24/160 (15) | 0.74 (0.34, 1.58) | 0.90 (0.39, 2.08) |
Adherence, visual analogue scale self-report, past month (%)b
|
p = 0.01 |
p = 0.17 | |
0− | 5/13 (39) | 1 | 1 |
80− | 10/46 (22) | 0.50 (0.29, 0.86) | 0.65 (0.35, 1.19) |
95+ | 21/163 (13) | ||
Adherence, dose-by-dose self-report, past four days (%) |
p = 0.04 |
p = 0.30 | |
0− | 4/9 (44) | 1 | 1 |
95+ | 32/213 (15) | 0.22 (0.06, 0.87) | 0.32 (0.06, 1.76) |
Adherence, pharmacy refill schedule, HAART start or 24 monthsb
|
p = 0.002 |
p = 0.009 | |
0− | 8/22 (36) | 1 | 1 |
80− | 12/53 (23) | 0.45 (0.28, 0.73) | 0.47 (0.27, 0.83) |
95+ | 16/147 (11) | ||
Treatment interruptions of ≥1 day, self-report, past month |
p = 0.003 |
p = 0.08 | |
None | 27/200 (14) | 1 | 1 |
Any | 9/22 (41) | 4.44 (1.73, 11.38) | 2.77 (0.91, 8.43) |
Unintentional underdosing |
p = 0.32 |
p = 0.30 | |
No | 27/180 (15) | 1 | 1 |
Yes | 9/42 (21) | 1.55 (0.67, 3.59) | 1.66 (0.65, 4.24) |
Factor |
p value, crude odds ratio (95 % CI) |
p value, adjusted odds ratio (95 % CI)a
|
---|---|---|
Age group (years)b
|
p = 0.69 |
p = 0.68 |
18− | 1 | 1 |
30− | 0.90 (0.52, 1.55) | 1.15 (0.60, 2.20) |
40+ | ||
Refugee status |
p = 0.19 |
p = 0.60 |
Host | 1 | 1 |
Refugee | 1.59 (0.77, 3.28) | 1.28 (0.52, 3.14) |
Sex |
p = 0.04 |
p = 0.05 |
Male | 1 | 1 |
Female | 0.41 (0.16, 1.04) | 0.39 (0.14, 1.05) |
Time on HAART (years)b
|
p = 0.79 |
p = 0.53 |
0− | 1 | 1 |
1− | 1.06 (0.68, 1.67) | 1.17 (0.69, 1.96) |
2+ | ||
Time from diagnosis to start (weeks)b
|
p = 0.03 |
p = 0.04 |
0− | 1 | 1 |
25− | 0.61 (0.39, 0.95) | 0.64 (0.41, 0.99) |
50+ | ||
Temporary migration (≥1 continuous month in past year) |
p < 0.001 |
p = 0.002 |
No | 1 | 1 |
Yes | 4.21 (1.87, 9.50) | 4.12 (1.70, 9.99) |
Average time to clinic (hours) |
p = 0.01 |
p = 0.02 |
0− | 1 | 1 |
1+ | 2.88 (1.14, 7.27) | 3.05 (1.09, 8.49) |
Adherence, pharmacy refill schedule, HAART start or 24 monthsb,c
|
p = 0.002 |
p = 0.007 |
0− | 1 | 1 |
80− | 0.45 (0.28, 0.73) | 0.47 (0.27, 0.81) |
95+ |